UBS Maintains Buy on Encompass Health, Raises Price Target to $110
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Andrew Mok has maintained a Buy rating on Encompass Health (NYSE:EHC) and raised the price target from $100 to $110.
September 25, 2024 | 4:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst Andrew Mok has reaffirmed a Buy rating for Encompass Health and increased the price target from $100 to $110, indicating positive expectations for the company's stock performance.
The increase in price target from $100 to $110 by UBS suggests a positive outlook on Encompass Health's future performance. Maintaining a Buy rating indicates confidence in the company's growth potential, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100